Metabolic syndrome common in ADT-, ARPI-treated prostate cancer
Approximately 40% of men with prostate cancer treated with concurrent androgen deprivation therapy and androgen receptor pathway inhibitors may develop metabolic syndrome within a year. A retrospective analysis of nearly 17,000 patients showed the first metabolic condition, usually hypertension, occurs within the…